Results 51 to 60 of about 20,309,433 (355)

An economic evaluation of the war on cancer [PDF]

open access: yesJournal of Health Economics, 2010
For decades, the US public and private sectors have committed substantial resources towards cancer research, but the societal payoff has not been well-understood. We quantify the value of recent gains in cancer survival, and analyze the distribution of value among various stakeholders.
Eric C. Sun   +5 more
openaire   +3 more sources

Fetal Akinesia/Hypokinesia and Arthrogryposis of Neuromuscular Origin: Etiologic Groups, Genetics, and Phenotypic Spectrum

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To provide a comprehensive clinical and genetic characterization of individuals with arthrogryposis multiplex congenita (AMC), focusing on the distribution of genetic etiologies across the neuromuscular spectrum and comparing myogenic and neurogenic subtypes. Methods A total of 105 individuals with AMC were clinically and genetically
Florencia Pérez‐Vidarte   +13 more
wiley   +1 more source

Economic evaluation of screening for open angle glaucoma [PDF]

open access: yes, 2008
Objectives: The aim of this study was to assess the cost-effectiveness of screening for open-angle glaucoma (OAG) in the United Kingdom, given that OAG is an important cause of blindness worldwide.
Burr, Jennifer Margaret   +3 more
core   +2 more sources

Economics notes: Costing in economic evaluation

open access: yesBMJ, 2000
This is another in an occasional series of notes on economics These notes are edited by James Raftery (J.P.RAFTERY@bham.ac.uk) As argued in previous notes, the perspective of an economic evaluation—societal or confined to some organisation—affects the range of both outcomes and costs that should be included.
openaire   +4 more sources

Realism and resources: Towards more explanatory economic evaluation

open access: yesEvaluation, 2016
To be successfully and sustainably adopted, policy-makers, service managers and practitioners want public programmes to be affordable and cost-effective, as well as effective.
Robert Anderson, R. Hardwick
semanticscholar   +1 more source

Factors for Rituximab Refractoriness in AQP4‐IgG+ NMOSD: A Cohort Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition of the central nervous system (CNS), often associated with aquaporin‐4 antibodies (AQP4‐IgG). Rituximab, a CD20+ B‐cell depleting monoclonal antibody, is widely used as first‐line therapy.
Mariano Marrodan   +8 more
wiley   +1 more source

Community Economic Development Initiative (CEDI) Programme Evaluation [PDF]

open access: yes, 2008
Shotton Colliery Community Economic Development Initiative (CEDI) began in 2007. It is one of three CEDI areas funded through the Single Programme. CEDI builds on a previous County Durham-wide programme, Settlement Renewal Initiatives (SRIs), which ended
Davidson, Gill
core  

Technical-economic aspects of the use of technological process of deforming broaching [PDF]

open access: yes, 2020
The article gives a definition of the technical and economic potential of the application of the deforming broaching process. Research of the consequences of introducing deforming broaching into technological processes at manufacturing enterprises is ...
Sardak, Sergii   +1 more
core  

Economics Notes: Types of economic evaluation

open access: yesBMJ, 1999
The pursuit of efficiency in the healthcare sector requires priority to be given to those treatments which provide the greatest benefit per unit of cost. Alternative interventions often have to be compared to determine whether a change in the mix of interventions would increase efficiency. Although economic evaluations approach costs in a common format,
Sarah Byford   +2 more
openaire   +4 more sources

An economic evaluation of lung transplantation [PDF]

open access: yesThe Journal of Thoracic and Cardiovascular Surgery, 2002
This study was undertaken to determine the cost per quality-adjusted life-year gained with lung transplantation relative to medical treatment for end-stage lung disease in the United Kingdom.Patients on the transplant waiting list were used to represent medical treatment.
A.J. Murday   +3 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy